Last 24 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.68 | — | — | 0.30 | — | — | — | — | — | — | — | 0.42 | — | — | — | — | — | 1.24 | 2.57 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.23 | 0.25 | 0.23 | 0.10 | 0.38 | 0.18 | 0.13 | 0.12 | 0.21 | 0.15 | 0.18 | 0.14 | 0.34 | 0.60 | 0.47 | 0.60 | 1.38 | 1.96 | 1.46 | 2.30 | — |
| — | +38.2% | +82.4% | -18.9% | +78.3% | +26.3% | -27.2% | -14.4% | -36.8% | -75.9% | -62.1% | -76.8% | -75.6% | -69.2% | -68.1% | -73.7% | — | — | — | — | — | |
| P/B Ratio | 0.92 | 2.05 | 1.56 | 0.63 | — | — | 9.41 | 1.36 | 1.39 | 0.42 | — | 1.24 | 11.55 | 1.97 | 0.97 | 1.03 | 1.06 | 2.03 | 3.28 | 7.43 | — |
| — | — | -83.5% | -53.3% | — | — | — | +9.7% | -88.0% | -78.8% | — | +20.6% | +993.5% | -2.9% | -70.3% | -86.2% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 93.12 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 0.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 0.28 | — | — | — | — | — | 1.07 | — | 0.67 | — | — | — | — | — | — | 1.52 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.7% | 79.9% | 81.8% | 94.9% | 70.4% | 70.5% | 61.6% | 58.0% | 45.9% | 44.6% | 50.1% | 49.3% | 48.4% | 50.6% | 47.3% | 48.2% | 48.5% | 42.7% | 47.2% | 47.9% | 47.2% |
| — | +13.4% | +32.8% | +63.6% | +53.5% | +57.9% | +23.1% | +17.6% | -5.2% | -11.9% | +5.7% | +2.4% | -0.2% | +18.5% | +0.3% | +0.5% | +2.9% | -9.0% | +3.0% | -0.9% | +4.1% | |
| Operating Margin | -21.9% | -4.4% | -42.8% | 39.5% | -89.8% | -56.2% | -52.9% | -13.6% | -55.0% | -64.7% | -69.2% | -36.5% | -51.9% | -148.8% | -62.9% | -55.4% | -84.2% | -139.4% | -31.9% | -20.5% | -371.6% |
| — | +92.2% | +19.1% | +389.9% | -63.2% | +13.1% | +23.5% | +62.6% | -6.0% | +56.5% | -10.0% | +34.2% | +38.3% | -6.7% | -97.2% | -170.2% | +77.3% | -121.3% | +57.1% | -835.0% | -358.5% | |
| Net Margin | -25.3% | -5.0% | -47.1% | 33.0% | -95.1% | -59.0% | -48.9% | -11.1% | -62.9% | -3.3% | -132.1% | 33.3% | -71.3% | -168.2% | -85.6% | -27.5% | -59.4% | -19.1% | 57.0% | -158.2% | -369.5% |
| — | +91.5% | +3.7% | +396.7% | -51.3% | -1698.4% | +63.0% | -133.4% | +11.8% | +98.1% | -54.3% | +221.2% | -20.1% | -782.0% | -250.1% | +82.6% | +83.9% | +69.5% | +176.6% | -7191.3% | -316.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -141.3% | -10.0% | -57.4% | 142.8% | — | — | -171.5% | -28.0% | -69.0% | -9.4% | — | 120.9% | -154.5% | -82.2% | -36.8% | -12.0% | -12.9% | -4.9% | 38.7% | -127.9% | — |
| — | — | +66.5% | +609.6% | — | — | — | -123.2% | +55.4% | +88.6% | — | +1109.1% | -1098.8% | -1576.1% | -195.2% | +90.6% | — | +99.4% | +144.4% | -3908.5% | — | |
| ROA | -41.6% | -2.5% | -17.8% | 25.6% | -37.4% | -29.0% | -21.7% | -6.9% | -28.3% | -1.1% | -39.8% | 11.4% | -17.9% | -24.9% | -16.1% | -5.3% | -4.7% | -1.7% | 10.9% | -42.3% | -96.9% |
| — | +91.5% | +18.0% | +473.1% | -32.2% | -2502.8% | +45.3% | -160.5% | -58.3% | +95.5% | -146.8% | +316.2% | -278.3% | -1408.9% | -248.3% | +87.6% | +95.1% | +91.3% | +169.0% | -5389.9% | — | |
| ROIC | -100.2% | -4.8% | -36.6% | 110.7% | — | — | -97.5% | -36.2% | -64.0% | -127.3% | -119.7% | -62.5% | -129.7% | -139.3% | -66.1% | -272.6% | — | — | — | — | — |
| — | — | +62.5% | +406.1% | — | — | +18.6% | +42.1% | +50.6% | +8.6% | -81.2% | +77.1% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 1.26 | 1.27 | 0.59 | — | — | 10.37 | 1.11 | 0.18 | 0.13 | — | 1.13 | 2.71 | 0.31 | 0.07 | 0.06 | — | — | — | — | — |
| — | — | -87.7% | -47.1% | — | — | — | -1.4% | -93.4% | -56.9% | — | +1898.3% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | 0.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.52 | 1.18 | 1.20 | 1.52 | 1.15 | 0.96 | 1.40 | 1.72 | 1.53 | 1.89 | 1.44 | 1.28 | 1.02 | 1.27 | 1.82 | 2.06 | 2.83 | 3.16 | 3.44 | 3.36 | 0.90 |
| — | +23.4% | -13.9% | -11.7% | -25.2% | -49.3% | -2.6% | +35.0% | +50.9% | +48.0% | -21.1% | -38.2% | -64.1% | -59.7% | -47.1% | -38.5% | +215.1% | +0.0% | -13.4% | -24.2% | — | |
| Quick Ratio | 1.40 | 1.08 | 1.09 | 1.40 | 0.80 | 0.75 | 0.80 | 1.17 | 0.94 | 1.46 | 0.94 | 0.67 | 0.47 | 0.69 | 1.49 | 1.72 | 2.12 | 2.57 | 3.05 | 3.03 | 0.42 |
| — | +43.2% | +35.9% | +19.8% | -14.8% | -48.5% | -14.9% | +73.8% | +102.8% | +111.3% | -36.8% | -60.9% | -78.1% | -73.1% | -51.0% | -43.2% | +410.4% | +72.1% | +60.7% | +7.4% | — | |
| Interest Coverage | -22.25 | -4.71 | -39.02 | 48.00 | -58.85 | -45.11 | -34.03 | -24.44 | -628.56 | 0.62 | -6.34 | 16.11 | -39.91 | -80.18 | -81.12 | -29.26 | -26.88 | -8.24 | 61.12 | -156.61 | -176.84 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BFRI stock.
Biofrontera Inc.'s current P/E is -1.7x. The average P/E over the last 1 quarters is 0.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Biofrontera Inc.'s current operating margin is -21.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Biofrontera Inc.'s business trajectory between earnings reports.